FDA Approves Herpes Virus Treatment for Melanoma

Federal regulators just approved a groundbreaking melanoma treatment that transforms the herpes virus into a cancer-fighting weapon. For patients whose advanced skin cancer stopped responding to standard treatments, this innovative therapy offers new hope.

The FDA granted accelerated approval to Tudriqev, a therapy that reprograms the herpes simplex virus to attack melanoma cells from the inside. Scientists trained the virus to multiply only in cancer cells, destroying tumors while triggering the body's immune system to hunt down remaining cancer cells.

This double attack shrank tumors in 24% of the 91 patients tested in clinical trials. Some patients responded for more than a year, with the typical response lasting over 14 months.

The treatment fills a critical gap for adults whose melanoma can't be surgically removed and isn't responding to standard immunotherapy drugs. Patients receive injections directly into their tumors every two weeks, combined with infusions of the immunotherapy drug nivolumab starting in week three.

"For patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited," said Karim Mikhail, acting director of the FDA's Center for Biologics Evaluation and Research. "Today's important milestone gives oncologists a meaningful new tool and more patients a fighting chance."

The approval came after a challenging review process. The FDA initially rejected the treatment in April but reconsidered after hearing directly from melanoma patients at a July meeting, ultimately voting 10 to 3 in favor.

Why This Inspires

This approval represents more than just scientific innovation. It shows how regulators listened to patients whose voices carried the weight of lived experience fighting an aggressive disease with few options.

The therapy's journey from rejection to approval also highlights how patient advocacy can shape medical progress. When standard treatments fail, every new option becomes a lifeline worth fighting for.

Financial navigators at major oncology centers will help patients navigate the treatment's $450,000 list price through insurance coverage and aid programs. The drug developer must conduct additional trials to verify the therapy's benefits and maintain FDA approval.

Together, science and hope are giving patients what they need most: a fighting chance.